Ajanta Pharma (AJANTPHARM.NS) Osake Kurssi
Ajanta Pharma Kurssi
Liikevaihto on kasvanut 17,4 % vuodessa viimeisten 19 vuoden aikana 54,53 Mrd. INR:een. Osakekohtainen tulos on kasvanut 25,2 % vuodessa viimeisten 19 vuoden aikana. Ajanta Pharman nettomarginaali on nyt 19,4 %, laskenut 21,7 %:sta muutama vuosi sitten. Ajanta Pharman osinkotuotto on tällä hetkellä noin 0,85 %. Jakosuhde on noin 58 % tuloksesta. Osinko on kasvanut 30,5 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 3 304,80 INR, eli ali nykyhintaa 0,1 %. 20 analyytikosta 18 suosittaa ostoa — kokonaiskonsensus on Osta.
Ajanta Pharma osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Ajanta Pharma liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Ajanta Pharma -osakkeesta
The business model of Ajanta Pharma Ltd is centered around the manufacturing and marketing of generic pharmaceutical products. Ajanta Pharma specializes in the development, manufacture, and marketing of generic medicines across various therapeutic segments, including cardiovascular, dermatology, ophthalmology, and more. The company focuses on providing affordable and high-quality pharmaceutical products to customers globally. Ajanta Pharma's diverse product portfolio caters to the needs of diverse markets through its strong distribution network. With its commitment to innovation, quality, and customer satisfaction, Ajanta Pharma continues to establish itself as a leading player in the global pharmaceutical industry.
Ajanta Pharma Ltd is primarily active in the pharmaceutical industry.
The main competitors of Ajanta Pharma Ltd in the market include Sun Pharmaceutical Industries Ltd, Cipla Ltd, Lupin Ltd, and Dr. Reddy's Laboratories Ltd.
Ajanta Pharma Ltd is a leading pharmaceutical company headquartered in India. It was established in 1973 and has since witnessed substantial growth in the global healthcare industry. Ajanta Pharma specializes in the development, manufacturing, and marketing of high-quality generic and branded drugs. With a strong focus on research and development, the company has created a diverse product portfolio across numerous therapeutic areas. Ajanta Pharma's commitment to quality and affordability has enabled it to penetrate various international markets and gain a reputation as a reliable pharmaceutical provider. With a consistent track record of success, Ajanta Pharma continues to play a notable role in improving global healthcare access.
Ajanta Pharma Ltd has achieved several significant milestones. The company has successfully established a global presence by exporting its pharmaceutical products to over 50 countries. Ajanta Pharma Ltd has received various certifications and accreditations, including US FDA approval, WHO GMP certification, and ISO 9001:2015 certification for its manufacturing facilities. The company has also been recognized for its research and development capabilities, launching multiple innovative and affordable generic pharmaceutical products. With its strong commitment to quality and customer satisfaction, Ajanta Pharma Ltd has become a trusted name in the pharmaceutical industry globally.
Ajanta Pharma Ltd is primarily present in various countries and regions across the globe. The company has a significant presence in India, where it is headquartered. Additionally, Ajanta Pharma Ltd has established a strong foothold in the United States, Europe, Asia, Africa, and Latin America. With its expanding market presence, Ajanta Pharma Ltd continues to cater to the healthcare needs of patients worldwide, delivering quality pharmaceutical products and contributing to global healthcare.
Ajanta Pharma Ltd represents values of innovation, excellence, and integrity in the pharmaceutical industry. The company is committed to delivering high-quality and affordable healthcare solutions to patients worldwide. With a strong emphasis on research and development, Ajanta Pharma Ltd strives to continuously develop and introduce new, cutting-edge pharmaceutical products. Their corporate philosophy revolves around the belief in creating value for all stakeholders, including customers, employees, and shareholders. Through their dedicated efforts, Ajanta Pharma Ltd has established a reputation for providing safe and effective medications that improve the quality of people's lives globally.
Analyytikot asettavat tällä hetkellä Ajanta Pharma-osakkeelle keskimääräisen tavoitehinnan 3 309,98 INR (mediaani: 3 304,80 INR), mikä merkitsee +0,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.
20 analyytikkoa arvioi tällä hetkellä Ajanta Pharma-osaketta: 18 suosittaa ostoa, 1 pitoa ja 1 myyntiä.
Nykyisellä valuuttakurssilla Ajanta Pharma-osake noteerataan hintaan 31,52 EUR (3 307,70 INR).
Ajanta Pharma-osake (AJANTPHARM.NS) on listattuna 2 pörssissä, muun muassa: NSE (Indien) (AJANTPHARM.NS).
Ajanta Pharma Ltd is a multinational company based in India. It specializes in producing high-quality healthcare products, primarily generic drugs that are cheaper alternatives to branded medications. One of its main focuses is producing generics for treating sexual dysfunction. The company also manufactures a wide range of innovative medications in various therapeutic areas, including dermatology, ophthalmology, neurology, nephrology, and oncology. Some of its key products include Kamagra, an effective treatment for erectile dysfunction in men; Tadalafil, also known as Cialis, for improving erectile function; and Sildenafil Citrate, marketed as "Viagra". Ajanta Pharma Ltd also produces Active Pharmaceutical Ingredients (APIs) that are distributed globally and used in various medications. It is committed to providing high-quality medicines at affordable prices and strives to improve access to healthcare for everyone. The company emphasizes innovation and invests in research and development to meet customer needs. It also maintains strategic partnerships with international healthcare companies to expand its scientific expertise. Ajanta Pharma Ltd generated over $1 billion in revenue last year and employs around 9,800 people worldwide. It operates in more than 30 countries and has six modern manufacturing facilities in India. Overall, Ajanta Pharma Ltd aims to promote sustainable development in the healthcare sector and plans to further expand its presence in the coming years.
liikevaihto Ajanta Pharma on 54,53 Mrd. INR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Ajanta Pharma on 10,56 Mrd. INR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Ajanta Pharma:n hinta-voitto-suhde (P/E) on tällä hetkellä 39,18. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Ajanta Pharma-osakkeen arvostusta.
Ajanta Pharma:n hinta-myynti-suhde (P/S) on tällä hetkellä 7,59. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Ajanta Pharma-osakkeen arvostuskennuslukuna.
Ajanta Pharma:n Eulpool-laatuscore on 10/10.
Ajanta Pharma:n ISIN on INE031B01049. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Ajanta Pharma:n ticker on AJANTPHARM.NS. Tämä pörssinoteeraus käytetään Ajanta Pharma-osakkeiden kauppaan pörssissä.
Ajanta Pharma osake
Ajanta Pharma vertaisryhmä
Ajanta Pharma Ticker
Ajanta Pharma FIGI
Kaikki tunnusluvut ja syvällinen analyysi Ajanta Pharma:sta
Meidän osakeanalyysimme Ajanta Pharma-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Ajanta Pharma:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: